Tafamidis for treating transthyretin amyloidosis with cardiomyopathy

2.1 Tafamidis (Vyndaqel, Pfizer) is indicated for 'the treatment of wild‑type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM)'. Before the marketing authorisation was granted, tafamidis was available in the NHS through the early access to medicines scheme.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The price of tafamidis is £10,685.00 per 30‑capsule pack of 61 mg capsules (excluding VAT; company submission) giving an annual cost of £130,089.88. The company has a commercial arrangement, which would have applied if the technology had been recommended.